Filter Releases
 
Press Releases
Date Title and Summary View
Mar 10, 2017
WALTHAM, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that the U.S. Food and Drug Administra...
Feb 28, 2017
WALTHAM, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the Cowen and ...
Feb 23, 2017
US FDA PDUFA for abaloparatide-SC is March 30, 2017 Build out of Commercial Organization to be completed in 1Q 2017 24-month ACTIVExtend trial has concluded, Radius to report top-line results in 2Q 2017 WALTHAM, Mass., Feb. ...
Feb 1, 2017
— Results from interim analysis of the ACTIVExtend study of postmenopausal women with osteoporosis treated for 18 months with investigational drug abaloparatide-SC in the ACTIVE trial who were transitioned to alendronate in ACTIVExtend show statistically significant reductions at six months in the incidence of new vert...
Jan 31, 2017
WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017.In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 4:30 p.m. ET on Thurs...
Jan 6, 2017
WALTHAM, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annua...
Dec 8, 2016
 -3 patients had confirmed partial responses by RECIST criteria from ongoing Phase I studies with RAD1901 in patients with advanced estrogen receptor positive breast cancer- -In the Phase 1 dose escalation and expansion study, 14 heavily pretreated patients remained on RAD1901 for equal t...
Nov 3, 2016
ACTIVE Phase 3 trial results published in Journal of American Medical Association and Journal of Bone Mineral ResearchRadius to present three abstracts on RAD1901 at San Antonio Breast Cancer Symposium in DecemberWALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Radi...
Nov 1, 2016
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the ...
Oct 12, 2016
WALTHAM, Mass., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2016 financial results on Thursday, November 3, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Thur...
Sep 19, 2016
-Second Generation Transdermal Patch Achieves Pharmacokinetic Objectives— WALTHAM, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Radius Health Inc. (Nasdaq:RDUS) a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, onc...
Sep 18, 2016
WALTHAM, Mass., Sept. 18, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that additional positive results from the Phase 3 ACTIVE (...
Aug 30, 2016
WALTHAM, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of RAD1901, ...
Aug 16, 2016
WALTHAM, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and other endocrine diseases, today announced that positive results from the Phase 3 ACTIVE (...
Aug 4, 2016
Radius' NDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis was accepted for filing by FDA with a PDUFA date of March 30, 2017 An oral presentation on the clinical development progress of an optimized abaloparatide transdermal patch has been acce...
Aug 2, 2016
WALTHAM, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President an...
Jul 20, 2016
WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of abaloparatide ...
Jul 15, 2016
WALTHAM, Mass., July 15, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter 2016 financial results on Thursday, August 4, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Th...
Jul 5, 2016
WALTHAM, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that Chief Commer...
Jun 1, 2016
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and ...
May 31, 2016
WALTHAM, Mass., May 31, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that its New Drug Application (NDA) for abaloparatide—SC has b...
May 13, 2016
WALTHAM, Mass., May 13, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that, on May 8, 2016, the compensation committee of the company's board of di...
May 5, 2016
Radius submitted an NDA to the US FDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis and reduction of fracture risk.  An MAA for abaloparatide-SC is currently under regulatory review by the European Medicines Agency and we expect a CHMP scientific opinion...
May 2, 2016
WALTHAM, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President and C...
Apr 21, 2016
WALTHAM, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases today announced that President and Chief Executive Officer, Robert E. Ward, will present at t...
Apr 15, 2016
-Highlights from Phase 3 ACTIVE and ACTIVExtend Trials--New Results from WHO FRAX® assessment of ACTIVE Trial demonstrate consistency of fracture risk reduction--WCO-IOF-ESCEO Malaga 2016 is the largest forum for clinical research and edu...
Apr 12, 2016
WALTHAM, Mass., April 12, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter 2016 financial results on Thursday, May 5, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Thursday, May 5, 2016...
Apr 1, 2016
WALTHAM, Mass., April 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that, on March 28, 2016, the compensation committee of the company's board ...
Apr 1, 2016
WALTHAM, Mass., April 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced results from pre-specified subgroup analyses from its Phase 3 ACTIVE trial. The results d...
Mar 30, 2016
— Significant Reduction in the Risk of Vertebral, Nonvertebral, Clinical and Major Osteoporotic Fractures and Increases in Bone Mineral Density in Phase 3 Studies — — If approved, abaloparatide-SC would be the first new bone anabolic in the US since 2002...
Mar 11, 2016
WALTHAM, Mass., March 11, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms announced that, on&#...
Feb 29, 2016
WALTHAM, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms announced that President and Chief...
Feb 25, 2016
Management to host conference call today at 7:30 am ET.Radius submitted an MAA in Europe for the investigational drug abaloparatide-SC for the potential treatment of postmenopausal osteoporosis and reduction of fracture risk on November 17, 2015. The application has been validated by the EMA and...
Feb 2, 2016
WALTHAM, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2015 financial results on Thursday, February 25, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. ET on T...
Jan 28, 2016
WALTHAM, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will host a conference call and webcast on Thursday, January 28, 2016 at 4:30 p.m. ET to provide an update on the Company's progress on corporate milestones, including its clinical collaboration with Novartis to evaluate novel investig...
Jan 27, 2016
- Collaboration will evaluate Radius' investigational drug, RAD1901, in combination with Novartis investigational CDK4/6 inhibitor LEE011 for the treatment of breast cancer -Additional studies are planned to evaluate effects of combining RAD1901 with BYL719, Novartis investigati...
Dec 22, 2015
WALTHAM, Mass., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief ...
Dec 7, 2015
WALTHAM, Mass., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers announced today the appointment of Jean-Pierre (JP) Garnie...
Dec 7, 2015
WALTHAM, Mass., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patient...
Dec 4, 2015
Radius Initiates Human Pharmacokinetic Study of Optimized Transdermal Patch of Investigational Drug Abaloparatide WALTHAM, Mass., Dec. 04, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), today announced that the European Medicines Agency (EMA) has validated for review the Marketing ...
Nov 17, 2015
Today's submission represents the Company's first application to register a new medicineIf approved, abaloparatide-SC would be the first new bone anabolic in Europe since 2003Company provides update on timing for NDA submission WALTHAM, Mass., Nov. 17, 2015 (GL...
Nov 12, 2015
WALTHAM, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive breast cancers, announced toda...
Nov 11, 2015
WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief ...
Nov 5, 2015
WALTHAM, Mass., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing n...
Nov 2, 2015
WALTHAM, Mass., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive breast cancer, announced today that it will present new data o...
Oct 28, 2015
WALTHAM, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, announced today that it will release its t...
Oct 12, 2015
Radius Health announces positive Phase 3 data from the ACTIVExtend trial presented at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting First six months of top-line data from ACTIVExtend show that treatment with investigational drug abaloparatide-SC followed by ale...
Oct 10, 2015
WALTHAM, Mass., Oct. 10, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announces positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial, which showed that women with postmenopausal osteoporosis ...
Sep 22, 2015
WALTHAM, Mass., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) announced today that it plans to host a conference call and webcast on Thursday, September 24, 2015, to provide an update on the safety and tolerability profile of RAD1901, a selective estrogen receptor degrader, from the completed Phase...
Sep 9, 2015
WALTHAM, Mass., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS) (the "Company"), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that it has hi...
Aug 18, 2015
WALTHAM, Mass., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that Catherine Friedman, an in...
Aug 6, 2015
Management to host conference call today at 7:30 am EDT WALTHAM, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including h...
Aug 5, 2015
WALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief Executiv...
Jul 30, 2015
WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today that it will release its second quar...
Jul 28, 2015
WALTHAM, Mass., July 28, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced the clos...
Jul 27, 2015
WALTHAM, Mass., July 27, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS) (the "Company"), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that it has hi...
Jul 22, 2015
WALTHAM, Mass., July 22, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced th...
Jul 21, 2015
WALTHAM, Mass., July 21, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced th...
Jul 20, 2015
WALTHAM, Mass., July 20, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ:RDUS) (the "Company"), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that Debasish ...
Jul 15, 2015
WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or "we") (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that early ...
Jul 14, 2015
WALTHAM, Mass., July 14, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive breast cancer, announced today that it will present new data from mul...
Jun 17, 2015
Investigational drug abaloparatide-SC shows continued clinical benefit across the 25-month period with significant reductions in vertebral, nonvertebral, clinical and major osteoporotic fractures.In the first six months of ACTIVExtend, patients who previously completed 18 months of abaloparatide-SC administration experienced no new vertebral fractu...
Jun 3, 2015
WALTHAM, Mass., June 3, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief Executiv...
Jun 1, 2015
WALTHAM, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that it has engaged Myrtle Potter...
May 27, 2015
WALTHAM, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that President and Chief Execut...
May 8, 2015
WALTHAM, Mass., May 8, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that President and Chief Executi...
May 6, 2015
Management to host conference call today at 7:30 am ET WALTHAM, Mass., May 6, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive b...
Apr 30, 2015
WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that President and Chief Exec...
Apr 28, 2015
WALTHAM, Mass., April 28, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today that it will release its first quar...
Apr 10, 2015
WALTHAM, Mass., April 10, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that it has appointed Brent Hatzis-Schoch as Se...
Apr 9, 2015
WALTHAM, Mass., April 9, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), today announced that the ECTS-IBMS 2015 Scientific Program Committee has accepted "Treatment with Abaloparatide Significantly Reduces Wrist Fractures Compared to Teriparatide-Results of the Phase 3 ACTIVE Trial" for an ORAL COMMUNICATION in the HOT TOPICS Session a...
Mar 13, 2015
WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that its Chief Scientific Off...
Mar 10, 2015
Management to host conference call today at 7:30 am ET WALTHAM, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including ...
Mar 9, 2015
WALTHAM, Mass., March 9, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced several updates for the investigational drug RA...
Mar 2, 2015
WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today the appointment of Tony Rosenberg to its Board ...
Feb 24, 2015
WALTHAM, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its Vice President, Business Development & Strategy, Geoffrey A. Swire, will present at the BIO-Europe Spring 2015 Paris Expo Conference on Tuesday, March 10, 2015 at 5:00 p.m. Central European Time at the Porte de Versailles, Paris, France. ...
Feb 24, 2015
WALTHAM, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that President and Chief Execu...
Feb 19, 2015
WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2014 financial results on Tuesday, March 10, 2015. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. ET on Tuesday, March 10, 201...
Feb 16, 2015
WALTHAM, Mass., Feb. 16, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that President and CEO, Robert Ward, will present at the 2015 RBC Capital Markets Global Healthcare Conference on February 25th at 11:00 a.m. EST at the New York Palace Hotel in New York City. The Company's presentation will be webcast live on th...
Feb 3, 2015
WALTHAM, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that President and CEO, Robert Ward, will be presenting a company overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th, 2015 at 5:00 p.m. Eastern Time at the Waldorf Astoria in New York City The company presentation wi...
Jan 29, 2015
WALTHAM, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), today announced that the Annual Meeting Steering Committee of ENDO 2015 has selected the company's recently completed Phase 3 ACTIVE study of abaloparatide-SC in post menopausal osteoporosis for the Late-Breaker oral presentations session at the International Society of ...
Jan 28, 2015
WALTHAM, Mass., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced the closi...
Jan 22, 2015
WALTHAM, Mass., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediat...
Jan 20, 2015
WALTHAM, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it is commenci...
Jan 12, 2015
...
Dec 21, 2014
Study Meets Primary Endpoint of Reducing the Percentage of Patients with Incident Vertebral Fracture and Also Meets Important Secondary Endpoints: Adverse Events Consistent with Previous Clinical ExperienceRadius Remains on Track for Completion of the Ongoing 6-Month ACTIVExtend Study and NDA Submission in the Second Half of 2015Radius' Investigati...
Dec 19, 2014
WALTHAM, Mass., Dec. 19, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for its investigational drug RAD1901, a tissue-selective estrogen receptor degrader (SERD) being developed for potential use in met...
Dec 15, 2014
As a result of the annual re-ranking of the NASDAQ Biotechnology Index, NASDAQ announced today that Radius Health shares will be added to the index effective before the market open on Monday, December 22, 2014. WALTHAM, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) will be added to the NASDAQ Biotechnology Index (Na...
Dec 11, 2014
WALTHAM, Mass., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it presented data from a Phase 1 clinical study on estrogen receptor engagement by the investigational drug RAD1901, a tissue-selective estrogen receptor degrader (SERD), in a poster presentation at the 2014 San Antonio Breast Cancer Symposium (...
Nov 24, 2014
-- Multi-center, multi-national, double-blind, placebo-controlled trial in which postmenopausal women were randomized to receive 24-weeks of treatment with either daily subcutaneous injections of placebo, the investigational drug abaloparatide 20, 40 or 80-μg, or teriparatide 20-μg. A 24-week extension also was performed in a subset of su...
Nov 17, 2014
Company selected to present at Informa's Therapeutic Area Partnerships meeting at 1:30 pm ET on Thursday, November 20 in Boston WALTHAM, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its investigat...
Nov 17, 2014
WALTHAM, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that President and CEO, Robert Ward, is scheduled to present at the Jefferies Global London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on November 20 at the Waldorf Hilton in London.About Radius Health Radius is a science-driven bioph...
Nov 10, 2014
WALTHAM, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, reported its financial results for the third quar...
Nov 3, 2014
WALTHAM, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today the appointment of Dr. Willard H. Dere, to its Board of Directors. Dr. Dere was formerly at Amgen, where he led the development program of Prolia. "We are very pleased to welcome Dr. Willard Dere to the Radius Health Board," said President and CEO...
Oct 28, 2014
WALTHAM, Mass., Oct. 28, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its Vice President, Business Development & Strategy, Geoffrey A. Swire, will present at the BIO-Europe Conference on Wednesday, November 5, 2014 at 12:45 p.m. Central European Time at the Portalhaus Messe Frankfurt, in Frankfurt, Germany. BI...
Oct 23, 2014
WALTHAM, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today it is a sponsor of The Cancer Support Community's symposium, "The Patient Voice: The First Year of the Cancer Experience Registry," in recognition of National Breast Cancer Awareness Month. Radius is pleased to help be a sponsor of this patient-focus...
Oct 21, 2014
WALTHAM, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2014 financial results on Tuesday, November 11, 2014. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Tuesday, November 11, 2014 to disc...
Oct 2, 2014
WALTHAM, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, announced today that it has priced its public offeri...
Oct 1, 2014
WALTHAM, Mass., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it is commencing an underwritte...
Sep 25, 2014
Radius Health Summarizes Recent Presentations regarding its Investigational Drug Abaloparatide at the American Society for Bone and Mineral Research and for its Investigational Drug RAD1901 at the 4th Annual Brain Metastases Research and Emerging Therapy ConferenceInvestigational Drug Abaloparatide Currently in Phase 3 Clinical Development, Top Lin...
Sep 11, 2014
CAMBRIDGE, Mass., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its President and CEO, Robert Ward, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 2:00 p.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York. ...
Sep 8, 2014
Live Panel And Conference Call Scheduled for 7:30 a.m. CDT on September 15, 2014 Data Presented During Poster Session at ASBMR 2014 WALTHAM, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with oste...
Aug 28, 2014
WALTHAM, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, reports that the positron emission tomography (PET) imaging from the R...
Aug 19, 2014
CAMBRIDGE, Mass., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Te...
Aug 12, 2014
WALTHAM, Mass., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, reported its financial results for the second quarter ended June 30, 2...
Aug 7, 2014
CAMBRIDGE, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that its President and CEO, Robert Ward, will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014 at 10:30 a.m. Eastern Time at the Intercontinental Hotel in Boston. The presentation will be webcast live on the...
Aug 6, 2014
CAMBRIDGE, Mass., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter 2014 financial results on Tuesday, August 12, 2014. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8.30 a.m. ET on Tuesday, August 12, 2014 to discus...
Jun 18, 2014
CAMBRIDGE, Mass., June 18, 2014 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), will present scientific data from studies conducted with abaloparatide (BA058) at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014) in Chicago, Illinois, June 21-24, 2014. Abstracts related to Radius Health in...
Jun 5, 2014
CAMBRIDGE, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") announced today that it has priced its initial public offering of 6,500,000 shares of its common stock at a public offering price of $8.00 per share. In addition, Radius has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of com...
May 5, 2014
CAMBRIDGE, MA--(Marketwired - May 5, 2014) - Radius Health Announces Scientific Presentations at the 40th European Calcified Tissue Society (ECTS) Congress and at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014)Radius Health, Inc. will present scientific data from studies conducte...
Jan 9, 2014
CAMBRIDGE, MA--(Marketwired - Jan 9, 2014) - Radius Health, Inc. ("Radius") announced today that it has strengthened its management team with the addition of John Yates, M.D., as Chief Medical Officer and Greg Williams, Ph.D., as Chief Development Officer, and the promotion of Gary Hattersley, Ph.D., to Chief Scientific Officer. ...
Jan 9, 2014
CAMBRIDGE, MA--(Marketwired - Jan 9, 2014) - Radius Health, Inc. ("Radius"), a late-stage biopharmaceutical company focused on developing novel therapeutics for osteoporosis and other serious endocrine-mediated diseases, today announced topline results from a Phase 2 study of BA058, or abaloparatide1, the company's novel synthetic pepti...
Dec 17, 2013
CAMBRIDGE, MA--(Marketwired - Dec 17, 2013) - Radius Health, Inc. ("Radius") announced today the appointment of Robert Ward as President and Chief Executive Officer. Mr. Ward takes on the role of CEO at a dynamic time when Radius is advancing its osteoporosis program in late-stage human clinical trials: The lead program, BA058-SC -- a potential...
Apr 25, 2013
CAMBRIDGE, MA--(Marketwired - Apr 25, 2013) -   Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health co...
Apr 18, 2013
CAMBRIDGE, MA--(Marketwired - Apr 18, 2013) -    Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's hea...
Mar 12, 2013
CAMBRIDGE, MA--(Marketwire - Mar 12, 2013) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the ...
Feb 26, 2013
CAMBRIDGE, MA--(Marketwire - Feb 26, 2013) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announced today that it will present at the 33rd annual Cowen & Company Health Care Conference. Michael Wyzga, Presi...
Feb 8, 2013
CAMBRIDGE, MA--(Marketwire - Feb 8, 2013) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, a...
Jan 7, 2013
CAMBRIDGE, MA--(Marketwire - Jan 7, 2013) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, is providing an update regarding the progress of its Phase 3 study of BA058-Subcutaneous (SC). BA0...
Jan 3, 2013
CAMBRIDGE, MA--(Marketwire - Jan 3, 2013) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, completed enrollment for its randomized Phase 2 study of BA058-transdermal (BA058-TD) in healthy po...
Dec 20, 2012
Cambridge, Mass., December 20, 2012 – Radius Health, Inc. (“Radius”) and 3M Drug Delivery Systems are pleased to announce an exclusive partnership agreement for development and commercialization of BA058-transdermal (TD). BA058 is a novel, synthetic proprieta...
Nov 15, 2012
CAMBRIDGE, MA--(Marketwire - Nov 15, 2012) -  Radius Health, Inc. ("Radius"), announced today that it has voluntarily withdrawn its Registration Statement on Form S-1 (Registration No. 333-179397) (t...
Oct 12, 2012
CAMBRIDGE, MA--(Marketwire - Oct 12, 2012) - Radius Health, Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health...
Sep 27, 2012
Cambridge, MA, September 27, 2012 – Radius...
Jun 22, 2012
CAMBRIDGE, MA--(Marketwire - Jun 22, 2012) - Radius Health, a development-stage biopharmaceutical company focused on advanced therapies for healthy aging, will present scientific data from studies conducted with BA058 (a product candidate currently being developed for the treatment of postmenopausal osteoporosis) at ENDO 2012: The Endocrine Soc...
Apr 20, 2012
CAMBRIDGE, Mass., April  20, 2011—  Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, announcedtoday the appointment of Michael Franken as Senior Vice President and Chief Business Officer. Mr. Frank...
Feb 7, 2012
CAMBRIDGE, MA--(Marketwire - Feb 7, 2012) - Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, today announced that it has filed a registration statement with the Securities and Exchange Commission relating to a proposed public offering of...
Page:
...
Next Last
 
= add release to Briefcase